Understanding Treatment Patterns and Outcomes among Patients with De Novo Unresectable Locally Advanced or Metastatic Urothelial Cancer: A Population-Level Retrospective Analysis from Alberta, Canada
Despite a high disease burden, real-world data on treatment patterns in patients with unresectable locally advanced or metastatic urothelial carcinoma (la/mUC) in Canada are limited. This retrospective, longitudinal cohort study describes treatment patterns and survival in a population of patients w...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/29/10/599 |
| _version_ | 1827650813243162624 |
|---|---|
| author | Nimira Alimohamed Simrun Grewal Heidi S. Wirtz Zsolt Hepp Stephanie Sauvageau Devon J. Boyne Darren R. Brenner Winson Y. Cheung Tamer N. Jarada |
| author_facet | Nimira Alimohamed Simrun Grewal Heidi S. Wirtz Zsolt Hepp Stephanie Sauvageau Devon J. Boyne Darren R. Brenner Winson Y. Cheung Tamer N. Jarada |
| author_sort | Nimira Alimohamed |
| collection | DOAJ |
| description | Despite a high disease burden, real-world data on treatment patterns in patients with unresectable locally advanced or metastatic urothelial carcinoma (la/mUC) in Canada are limited. This retrospective, longitudinal cohort study describes treatment patterns and survival in a population of patients with de novo unresectable la/mUC from Alberta, Canada, diagnosed between 1 January 2015 and 31 December 2019, followed until mid-2020. The outcomes of interest were systemic therapy treatment patterns and overall survival (OS). Of 206 patients, most (65.0%, <i>n</i> = 134) did not receive any systemic therapies. Of 72 patients (35.0%) who received first-line systemic therapy, the median duration of treatment was 2.8 months (IQR 3.3). Thirty-five patients (48.6% of those who received first-line therapy) received subsequent second-line therapy, for a median of 3.0 months (IQR 3.3). In all patients (<i>n</i> = 206), the median OS from diagnosis was 5.3 months (95% CI, 4.5–7.0). In patients who received treatment, the median OS from the initiation of first-line and second-line systemic therapy was 9.1 (6.4–11.6) and 4.6 months (3.9–19.2), respectively. The majority of patients did not receive first-line systemic therapy, and, in those who did, survival outcomes were poor. This study highlights the significant unmet need for safe and efficacious therapies for patients with la/mUC in Canada. |
| first_indexed | 2024-03-09T20:24:14Z |
| format | Article |
| id | doaj.art-58c125ba29bf4bb786002ff86ce20d93 |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-09T20:24:14Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-58c125ba29bf4bb786002ff86ce20d932023-11-23T23:40:46ZengMDPI AGCurrent Oncology1198-00521718-77292022-10-0129107587759710.3390/curroncol29100599Understanding Treatment Patterns and Outcomes among Patients with De Novo Unresectable Locally Advanced or Metastatic Urothelial Cancer: A Population-Level Retrospective Analysis from Alberta, CanadaNimira Alimohamed0Simrun Grewal1Heidi S. Wirtz2Zsolt Hepp3Stephanie Sauvageau4Devon J. Boyne5Darren R. Brenner6Winson Y. Cheung7Tamer N. Jarada8Tom Baker Cancer Centre, University of Calgary, Calgary, AB T2N 4N2, CanadaSeagen Inc., Bothell, WA 98021, USASeagen Inc., Bothell, WA 98021, USASeagen Inc., Bothell, WA 98021, USASeagen Canada, Mississauga, ON L5N 1W1, CanadaOncology Outcomes (O2), Calgary, AB T2N 4N2, CanadaOncology Outcomes (O2), Calgary, AB T2N 4N2, CanadaOncology Outcomes (O2), Calgary, AB T2N 4N2, CanadaOncology Outcomes (O2), Calgary, AB T2N 4N2, CanadaDespite a high disease burden, real-world data on treatment patterns in patients with unresectable locally advanced or metastatic urothelial carcinoma (la/mUC) in Canada are limited. This retrospective, longitudinal cohort study describes treatment patterns and survival in a population of patients with de novo unresectable la/mUC from Alberta, Canada, diagnosed between 1 January 2015 and 31 December 2019, followed until mid-2020. The outcomes of interest were systemic therapy treatment patterns and overall survival (OS). Of 206 patients, most (65.0%, <i>n</i> = 134) did not receive any systemic therapies. Of 72 patients (35.0%) who received first-line systemic therapy, the median duration of treatment was 2.8 months (IQR 3.3). Thirty-five patients (48.6% of those who received first-line therapy) received subsequent second-line therapy, for a median of 3.0 months (IQR 3.3). In all patients (<i>n</i> = 206), the median OS from diagnosis was 5.3 months (95% CI, 4.5–7.0). In patients who received treatment, the median OS from the initiation of first-line and second-line systemic therapy was 9.1 (6.4–11.6) and 4.6 months (3.9–19.2), respectively. The majority of patients did not receive first-line systemic therapy, and, in those who did, survival outcomes were poor. This study highlights the significant unmet need for safe and efficacious therapies for patients with la/mUC in Canada.https://www.mdpi.com/1718-7729/29/10/599urothelial carcinomaCanadareal-world datatreatment patterns |
| spellingShingle | Nimira Alimohamed Simrun Grewal Heidi S. Wirtz Zsolt Hepp Stephanie Sauvageau Devon J. Boyne Darren R. Brenner Winson Y. Cheung Tamer N. Jarada Understanding Treatment Patterns and Outcomes among Patients with De Novo Unresectable Locally Advanced or Metastatic Urothelial Cancer: A Population-Level Retrospective Analysis from Alberta, Canada Current Oncology urothelial carcinoma Canada real-world data treatment patterns |
| title | Understanding Treatment Patterns and Outcomes among Patients with De Novo Unresectable Locally Advanced or Metastatic Urothelial Cancer: A Population-Level Retrospective Analysis from Alberta, Canada |
| title_full | Understanding Treatment Patterns and Outcomes among Patients with De Novo Unresectable Locally Advanced or Metastatic Urothelial Cancer: A Population-Level Retrospective Analysis from Alberta, Canada |
| title_fullStr | Understanding Treatment Patterns and Outcomes among Patients with De Novo Unresectable Locally Advanced or Metastatic Urothelial Cancer: A Population-Level Retrospective Analysis from Alberta, Canada |
| title_full_unstemmed | Understanding Treatment Patterns and Outcomes among Patients with De Novo Unresectable Locally Advanced or Metastatic Urothelial Cancer: A Population-Level Retrospective Analysis from Alberta, Canada |
| title_short | Understanding Treatment Patterns and Outcomes among Patients with De Novo Unresectable Locally Advanced or Metastatic Urothelial Cancer: A Population-Level Retrospective Analysis from Alberta, Canada |
| title_sort | understanding treatment patterns and outcomes among patients with de novo unresectable locally advanced or metastatic urothelial cancer a population level retrospective analysis from alberta canada |
| topic | urothelial carcinoma Canada real-world data treatment patterns |
| url | https://www.mdpi.com/1718-7729/29/10/599 |
| work_keys_str_mv | AT nimiraalimohamed understandingtreatmentpatternsandoutcomesamongpatientswithdenovounresectablelocallyadvancedormetastaticurothelialcancerapopulationlevelretrospectiveanalysisfromalbertacanada AT simrungrewal understandingtreatmentpatternsandoutcomesamongpatientswithdenovounresectablelocallyadvancedormetastaticurothelialcancerapopulationlevelretrospectiveanalysisfromalbertacanada AT heidiswirtz understandingtreatmentpatternsandoutcomesamongpatientswithdenovounresectablelocallyadvancedormetastaticurothelialcancerapopulationlevelretrospectiveanalysisfromalbertacanada AT zsolthepp understandingtreatmentpatternsandoutcomesamongpatientswithdenovounresectablelocallyadvancedormetastaticurothelialcancerapopulationlevelretrospectiveanalysisfromalbertacanada AT stephaniesauvageau understandingtreatmentpatternsandoutcomesamongpatientswithdenovounresectablelocallyadvancedormetastaticurothelialcancerapopulationlevelretrospectiveanalysisfromalbertacanada AT devonjboyne understandingtreatmentpatternsandoutcomesamongpatientswithdenovounresectablelocallyadvancedormetastaticurothelialcancerapopulationlevelretrospectiveanalysisfromalbertacanada AT darrenrbrenner understandingtreatmentpatternsandoutcomesamongpatientswithdenovounresectablelocallyadvancedormetastaticurothelialcancerapopulationlevelretrospectiveanalysisfromalbertacanada AT winsonycheung understandingtreatmentpatternsandoutcomesamongpatientswithdenovounresectablelocallyadvancedormetastaticurothelialcancerapopulationlevelretrospectiveanalysisfromalbertacanada AT tamernjarada understandingtreatmentpatternsandoutcomesamongpatientswithdenovounresectablelocallyadvancedormetastaticurothelialcancerapopulationlevelretrospectiveanalysisfromalbertacanada |